A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis by Vikas Gupta, Ruben A. Mesa, Michael W.N. Deininger, Candido E. Rivera, Shireen Sirhan, Carrie Baker Brachmann, Helen Collins, Jun Kawashima, Yan Xin, Srdan Verstovsek

Get full text